Patent ID: 9233109
Filing Date: 2016-01-12
CPC Classification: A61K,A61P

Claim Text:
1. A method of reducing nicotine-induced rewarding effects in a subject who smokes comprising: delivering to a subject in need thereof a pharmaceutical composition, wherein the pharmaceutical composition includes a therapeutically effective amount of each of a α7 N-acetylcholine receptor (nAChR)-selective partial agonist and a α4β2 nAChR partial agonist, or a pharmaceutically acceptable salt of one or both of the α7-selective partial agonist and the α4β2 nAChR partial agonist, and a pharmaceutically acceptable carrier, wherein the α7 nAChR-selective partial agonist is 3-(2,4-dimethoxybenzylidene)anabaseine (DiMeOBA) (GTS-21) and in an amount therapeutically effective for reducing depression induced in said subject by the α4β2 nAChR partial agonist, and wherein the α4β2 nAChR partial agonist is varenicline, and in an amount therapeutically effective for reducing nicotine-induced rewarding effects in a subject by reducing the agonist effect of nicotine on the α4β2 nAChR.